Endo kept at outperform by RBC

Endo Pharmaceuticals Holdings Inc. was maintained at outperform, above average risk, with a $40 price target by RBC Capital Markets analyst Ken Trbovich. The company reported second-quarter sales of $228 million compared with RBC's estimate of $211 million and consensus of $214 million. Net income of $58 million also beat the analyst's estimate of $53 million. Endo's earnings per share were $0.44, above RBC's estimate of $0.40 and consensus of $0.43. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 27 cents, or 0.89%, at $29.91 on volume of 942,654 shares versus the three-month running average of 1,249,190 shares. (Nasdaq: ENDO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.